Chief Executive Officer
Mr. Hoffmann is entirely dedicated to Network Immunology's systems approach to treating disease and optimizing health. Realizing the immense untapped value in the network approach to understanding immuno-regulation, Hoffmann co-founded Network Immunology with Chief Scientist, Dr. Geoffrey W. Hoffmann in 2003. In 2007, Hoffmann was appointed Manager of Business Development. In 2009, at a key juncture in the Company’s history, he was appointed President and CEO. Since then he has been a major driver behind the Company's development and expansion.
He has contributed to the assembling of a team with the scientific expertise, business acumen and financial and developmental resources necessary to advance Network Immunology’s platform immuno-therapeutic product, AbstimX™. With the help of this outstanding team, Hoffmann has grown Network Immunology from an idea-stage startup, to a substantial industry contender on the verge of tremendous success. The Company has advanced its leading-edge platform technology, treatment and product, AbstimX™, through the various pre-clinical stages, and development is now entering the stage of human trials.
As the central communications hub of the company, Hoffmann is working with Management, the Board of Directors and the Scientific Advisory Board to advance AbstimX™ through the clinic to the stage of commercialization. Hoffmann ensures the Company continues to take actions toward increasing shareholder value, including securing commercial licensing agreements that provide robust returns on investment for Network Immunology stakeholders, as well as fulfilling on the Company's stated mission, which is to enhance the quality of human and animal lives.